The objective of this proposal is to study the functional role of renal (tissue) kallikrein-binding protein in hypertension. Tissue kallikrein are a group of homologous serine proteinases, encoded by a multigene family and involved in the processing of bioactive peptides and hormones. Kallikrein and its products play important roles in cellular homeostasis and blood pressure regulation. Although the biochemistry and regulation of kallikrein gene expression in normal and disease states have been extensively studied, information regarding factors which modulate kallikrein function is very limited. We have recently identified a novel kallikreinbinding protein in rat and human which forms and irreversible complex with tissue kallikrein. The binding protein in rat and human which form an irreversible complex with tissue kallikrein. The binding protein is defective in spontaneously hypertensive rats (SHR), suggesting that it may be a contributing factor in the hypertensive phenotype of SHR.
The specific aims of this study are: 1) to purify and characterize kallikrein-binding protein; develop monoclonal and polyclonal antibodies for determining distribution, quantities and localization of kallikrein- binding protein by binding assays, radioimmunoassays, Western blotting, immunohistochemistry and for physiological studies; 2) to elucidate the role of kallikrein-binding protein in the regulation of kallikrein bioavailability by in vivo clearance and catabolism studies; 3) to isolate cDna clones encoding the kallikrein-binding protein from a rat liver cDNA library and to use these clones to identify and localize kallikreinbinding protein gene expression by Northern, dot blot and in situ cDNA-mRNA hybridization; 4) to isolate and characterize the gene encoding the kallikreinbinding protein from a rat genomic library and to identify the potential cis- and trans-acting elements involved in tissue-specific expression of the gene by deletion analysis and nuclear protein binding assays; 5) to analyze restriction fragment length polymorphisms associated with the kallikrein-binding protein gene in genetically hypertensive animal models. The information gained form these studies should provide a better understanding of the kallikrein-kinin system's role in hypertension.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL044083-01
Application #
3362829
Study Section
Cardiovascular and Renal Study Section (CVB)
Project Start
1990-02-01
Project End
1995-01-31
Budget Start
1990-02-01
Budget End
1991-01-31
Support Year
1
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Type
Schools of Dentistry
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Chao, Julie; Bledsoe, Grant; Chao, Lee (2016) Protective Role of Kallistatin in Vascular and Organ Injury. Hypertension 68:533-41
Chao, Julie; Bledsoe, Grant; Chao, Lee (2014) Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res 69:37-57
Li, Pengfei; Bledsoe, Grant; Yang, Zhi-Rong et al. (2014) Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology 142:216-26
Zhang, Jingmei; Yang, Zhirong; Li, Pengfei et al. (2013) Kallistatin antagonizes Wnt/*-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem 379:295-301
Zhu, Haidong; Chao, Julie; Kotak, Ishita et al. (2013) Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. Metabolism 62:642-6
Liu, Yuying; Bledsoe, Grant; Hagiwara, Makato et al. (2012) Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol 303:F1230-8
Shen, Bo; Chao, Lee; Chao, Julie (2010) Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol 298:H1048-54
Chao, Julie; Shen, Bo; Gao, Lin et al. (2010) Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem 391:345-55
Yin, Hang; Gao, Lin; Shen, Bo et al. (2010) Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension 56:260-7
Shen, Bo; Gao, Lin; Hsu, Yi-Te et al. (2010) Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol 299:H1419-27

Showing the most recent 10 out of 68 publications